{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:49:39Z","timestamp":1780343379489,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["FISR2019_00374 MeDyCa-B84G19000200008"],"award-info":[{"award-number":["FISR2019_00374 MeDyCa-B84G19000200008"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Prin 2022 PNRR-SOLAR-B53D23025100001"],"award-info":[{"award-number":["Prin 2022 PNRR-SOLAR-B53D23025100001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministero delle Imprese e del Made in Italy","award":["Nabucco no. 1682"],"award-info":[{"award-number":["Nabucco no. 1682"]}]},{"name":"POR-FESR","award":["EPIGENIUS-SARS-CoV-2-E93C22001650002"],"award-info":[{"award-number":["EPIGENIUS-SARS-CoV-2-E93C22001650002"]}]},{"name":"The National Recovery and Resilience Plan","award":["Law Decree 6 May 2021"],"award-info":[{"award-number":["Law Decree 6 May 2021"]}]},{"name":"The National Recovery and Resilience Plan","award":["n. 59"],"award-info":[{"award-number":["n. 59"]}]},{"name":"The National Recovery and Resilience Plan","award":["converted"],"award-info":[{"award-number":["converted"]}]},{"name":"The National Recovery and Resilience Plan","award":["modified as to Law no. 101\/2021"],"award-info":[{"award-number":["modified as to Law no. 101\/2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Leukemia-secreted extracellular vesicles (EVs) carry biologically active cargo that promotes cancer-supportive mechanisms, including aberrant proliferative signaling, immune escape, and drug resistance. However, how antineoplastic drugs affect EV secretion and cargo sorting remains underexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Leukemia-secreted extracellular vesicles (EVs) were isolated by Differential UltraCentrifugation, and their miRNome and proteomic profiling cargo were analyzed following treatment with SAHA (Vorinostat) in Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML). The epigenetic modulation of leukemia-secreted EVs content on interesting key target molecules was validated, and their differential functional impact on cellular viability, cell cycle progression, apoptosis, and tumorigenicity was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SAHA significantly alters the cargo of Leukemia-derived EVs, including miR-194-5p and its target BCLAF1 (mRNA and protein)<jats:italic>,<\/jats:italic> key regulators of Leukemia cell survival and differentiation. SAHA upregulates miR-194-5p expression while selective loading BCLAF1 into EVs, reducing the miRNA levels in the same compartment. Additionally, SAHA alters miRNA profile and proteomic composition associated with leukemic EVs, altering their tumor-supportive potential, with differential effects observed between AML and CML. Furthermore, in silico predictions suggest that these modified EVs may influence cell sensitivity to antineoplastic agents, suggesting a dual role for SAHA in impairing oncogenic signaling while enhancing therapeutic responsiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In conclusion, the capacity of SAHA to modulate secretion and molecular composition of Leukemia-secreted EVs, alongside its direct cytotoxic effects, underscores its potential in combination therapies aimed to overcoming refractory phenotype by targeting EV-mediated communication.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12967-025-06361-1","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:20:41Z","timestamp":1744294841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vorinostat impairs the cancer-driving potential of leukemia-secreted extracellular vesicles"],"prefix":"10.1186","volume":"23","author":[{"given":"Crescenzo","family":"Massaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sgueglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Pieragostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Lanuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cufaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Della","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena Rubina","family":"Baglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarla","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-698X","authenticated-orcid":false,"given":"Carmela","family":"Dell\u2019Aversana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"13","key":"6361_CR1","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325\u201336.","journal-title":"Blood"},{"issue":"12","key":"6361_CR2","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/leu.2009.175","volume":"23","author":"F Ayala","year":"2009","unstructured":"Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009;23(12):2233\u201341.","journal-title":"Leukemia"},{"issue":"3","key":"6361_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1124\/pr.112.005983","volume":"64","author":"E van der Pol","year":"2012","unstructured":"van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64(3):676\u2013705.","journal-title":"Pharmacol Rev"},{"issue":"7","key":"6361_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/cells8070727","volume":"8","author":"LM Doyle","year":"2019","unstructured":"Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8(7):727.","journal-title":"Cells"},{"issue":"1","key":"6361_CR5","doi-asserted-by":"publisher","first-page":"1560809","DOI":"10.1080\/20013078.2018.1560809","volume":"8","author":"K Takov","year":"2019","unstructured":"Takov K, Yellon DM, Davidson SM. Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential. J Extracell Vesicles. 2019;8(1):1560809.","journal-title":"J Extracell Vesicles"},{"key":"6361_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-0716-2823-2_5","volume":"2595","author":"E D'Agostino","year":"2023","unstructured":"D\u2019Agostino E, Muro A, Sgueglia G, Massaro C, Dell\u2019Aversana C, Altucci L. Exosomal MicroRNAs: comprehensive methods from exosome isolation to miRNA extraction and purity analysis. Methods Mol Biol. 2023;2595:75\u201392.","journal-title":"Methods Mol Biol"},{"key":"6361_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.copbio.2019.01.005","volume":"60","author":"CY Kao","year":"2019","unstructured":"Kao CY, Papoutsakis ET. Extracellular vesicles: exosomes, microparticles, their parts, and their targets to enable their biomanufacturing and clinical applications. Curr Opin Biotechnol. 2019;60:89\u201398.","journal-title":"Curr Opin Biotechnol"},{"issue":"10","key":"6361_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/pharmaceutics12100980","volume":"12","author":"C Massaro","year":"2020","unstructured":"Massaro C, Sgueglia G, Frattolillo V, Baglio SR, Altucci L, Dell\u2019Aversana C. Extracellular vesicle-based nucleic acid delivery: current advances and future perspectives in cancer therapeutic strategies. Pharmaceutics. 2020;12(10):980.","journal-title":"Pharmaceutics"},{"issue":"12","key":"6361_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.dld.2009.04.006","volume":"41","author":"JL Qu","year":"2009","unstructured":"Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ, et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K\/Akt and MAPK\/ERK activation. Dig Liver Dis. 2009;41(12):875\u201380.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"6361_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12967-020-02426-5","volume":"18","author":"M Ahmadi","year":"2020","unstructured":"Ahmadi M, Rezaie J. Tumor cells derived-exosomes as angiogenenic agents: possible therapeutic implications. J Transl Med. 2020;18(1):249.","journal-title":"J Transl Med"},{"issue":"1","key":"6361_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-020-02609-0","volume":"18","author":"K Xu","year":"2020","unstructured":"Xu K, Liu Q, Wu K, Liu L, Zhao M, Yang H, et al. Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases. J Transl Med. 2020;18(1):432.","journal-title":"J Transl Med"},{"key":"6361_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-015-0181-x","volume":"8","author":"X Zhang","year":"2015","unstructured":"Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8:83.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"6361_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/leu.2009.76","volume":"23","author":"M Bebawy","year":"2009","unstructured":"Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23(9):1643\u20139.","journal-title":"Leukemia"},{"issue":"23","key":"6361_CR14","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.1158\/0008-5472.CAN-05-2021","volume":"65","author":"I Ifergan","year":"2005","unstructured":"Ifergan I, Scheffer GL, Assaraf YG. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res. 2005;65(23):10952\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"6361_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-019-1114-z","volume":"18","author":"X Wang","year":"2019","unstructured":"Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, et al. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 2019;18(1):182.","journal-title":"Mol Cancer"},{"issue":"12","key":"6361_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers11121823","volume":"11","author":"S Faict","year":"2019","unstructured":"Faict S, Oudaert I, D\u2019Auria L, Dehairs J, Maes K, Vlummens P, et al. The transfer of sphingomyelinase contributes to drug resistance in multiple myeloma. Cancers (Basel). 2019;11(12):1823.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"6361_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12967-021-03215-4","volume":"20","author":"C Li","year":"2022","unstructured":"Li C, Zhou T, Chen J, Li R, Chen H, Luo S, et al. The role of Exosomal miRNAs in cancer. J Transl Med. 2022;20(1):6.","journal-title":"J Transl Med"},{"issue":"11","key":"6361_CR18","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/leu.2017.64","volume":"31","author":"C Dell'Aversana","year":"2017","unstructured":"Dell\u2019Aversana C, Giorgio C, D\u2019Amato L, Lania G, Matarese F, Saeed S, et al. miR-194-5p\/BCLAF1 deregulation in AML tumorigenesis. Leukemia. 2017;31(11):2315\u201325.","journal-title":"Leukemia"},{"issue":"1","key":"6361_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/ijms22010048","volume":"22","author":"M Marchisio","year":"2020","unstructured":"Marchisio M, Simeone P, Bologna G, Ercolino E, Pierdomenico L, Pieragostino D, et al. Flow cytometry analysis of circulating extracellular vesicle subtypes from fresh peripheral blood samples. Int J Mol Sci. 2020;22(1):48.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"6361_CR20","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.3390\/ijms21217885","volume":"21","author":"P Simeone","year":"2020","unstructured":"Simeone P, Celia C, Bologna G, Ercolino E, Pierdomenico L, Cilurzo F, et al. Diameters and fluorescence calibration for extracellular vesicle analyses by flow cytometry. Int J Mol Sci. 2020;21(21):7885.","journal-title":"Int J Mol Sci"},{"key":"6361_CR21","doi-asserted-by":"crossref","unstructured":"Serafini FL, Lanuti P, Delli Pizzi A, Procaccini L, Villani M, Taraschi AL, et al. Diagnostic impact of radiological findings and extracellular vesicles: are we close to radiovesicolomics? Biology (Basel). 2021;10(12).","DOI":"10.3390\/biology10121265"},{"issue":"5","key":"6361_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/humrep\/deaa364","volume":"36","author":"C Dell'Aversana","year":"2021","unstructured":"Dell\u2019Aversana C, Cuomo F, Longobardi S, D\u2019Hooghe T, Caprio F, Franci G, et al. Age-related miRNome landscape of cumulus oophorus cells during controlled ovarian stimulation protocols in IVF cycles. Hum Reprod. 2021;36(5):1310\u201325.","journal-title":"Hum Reprod"},{"issue":"12","key":"6361_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083018","volume":"8","author":"I Lepore","year":"2013","unstructured":"Lepore I, Dell\u2019Aversana C, Pilyugin M, Conte M, Nebbioso A, De Bellis F, et al. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and\/or b. PLoS ONE. 2013;8(12): e83018.","journal-title":"PLoS ONE"},{"issue":"1","key":"6361_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13287-015-0116-z","volume":"6","author":"SR Baglio","year":"2015","unstructured":"Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Perez Lanzon M, Zini N, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015;6(1):127.","journal-title":"Stem Cell Res Ther"},{"key":"6361_CR25","doi-asserted-by":"crossref","unstructured":"Potenza F, Cufaro MC, Di Biase L, Panella V, Di Campli A, Ruggieri AG, et al. Proteomic Analysis of Marinesco-Sjogren Syndrome Fibroblasts Indicates Pro-Survival Metabolic Adaptation to SIL1 Loss. Int J Mol Sci. 2021;22(22).","DOI":"10.3390\/ijms222212449"},{"issue":"7","key":"6361_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cells11071160","volume":"11","author":"V Damiani","year":"2022","unstructured":"Damiani V, Cufaro MC, Fucito M, Dufrusine B, Rossi C, Del Boccio P, et al. Proteomics approach highlights early changes in human fibroblasts-pancreatic ductal adenocarcinoma cells crosstalk. Cells. 2022;11(7):1160.","journal-title":"Cells"},{"issue":"23","key":"6361_CR27","doi-asserted-by":"publisher","first-page":"14913","DOI":"10.3390\/ijms232314913","volume":"23","author":"G Catitti","year":"2022","unstructured":"Catitti G, Cufaro MC, De Bellis D, Cicalini I, Vespa S, Tonelli F, et al. Extracellular vesicles in regenerative processes associated with muscle injury recovery of professional athletes undergoing sub maximal strength rehabilitation. Int J Mol Sci. 2022;23(23):14913.","journal-title":"Int J Mol Sci"},{"issue":"D1","key":"6361_CR28","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol Y, Bai J, Bandla C, Garcia-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543\u201352.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"6361_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12967-021-02985-1","volume":"19","author":"L Yin","year":"2021","unstructured":"Yin L, Liu X, Shao X, Feng T, Xu J, Wang Q, et al. The role of exosomes in lung cancer metastasis and clinical applications: an updated review. J Transl Med. 2021;19(1):312.","journal-title":"J Transl Med"},{"issue":"6","key":"6361_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1101\/gad.292318.116","volume":"31","author":"R Rodriguez-Barrueco","year":"2017","unstructured":"Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, et al. miR-424(322)\/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 2017;31(6):553\u201366.","journal-title":"Genes Dev"},{"key":"6361_CR31","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/CMAR.S235794","volume":"12","author":"T Zhan","year":"2020","unstructured":"Zhan T, Zhu Q, Han Z, Tan J, Liu M, Liu W, et al. miR-455-3p functions as a tumor suppressor by restraining Wnt\/beta-catenin signaling via TAZ in pancreatic cancer. Cancer Manag Res. 2020;12:1483\u201392.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"6361_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-016-1018-2","volume":"14","author":"R Frazzi","year":"2016","unstructured":"Frazzi R, Auffray C, Ferrari A, Filippini P, Rutella S, Cesario A. Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies. J Transl Med. 2016;14(1):252.","journal-title":"J Transl Med"},{"issue":"12","key":"6361_CR33","doi-asserted-by":"publisher","first-page":"e202201643","DOI":"10.26508\/lsa.202201643","volume":"5","author":"AM Quemener","year":"2022","unstructured":"Quemener AM, Bachelot L, Aubry M, Avner S, Leclerc D, Salbert G, et al. Non-canonical miRNA-RNA base-pairing impedes tumor suppressor activity of miR-16. Life Sci Alliance. 2022;5(12):e202201643.","journal-title":"Life Sci Alliance."},{"issue":"1","key":"6361_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12967-020-02652-x","volume":"19","author":"P Li","year":"2021","unstructured":"Li P, Xin H, Lu L. Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB. J Transl Med. 2021;19(1):4.","journal-title":"J Transl Med"},{"key":"6361_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118239","volume":"259","author":"N Dastmalchi","year":"2020","unstructured":"Dastmalchi N, Hosseinpourfeizi MA, Khojasteh SMB, Baradaran B, Safaralizadeh R. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN\/PI3K\/AKT\/mTOR signaling pathway. Life Sci. 2020;259: 118239.","journal-title":"Life Sci"},{"issue":"3","key":"6361_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3727\/096504018X15220579006875","volume":"27","author":"H Yunqi","year":"2019","unstructured":"Yunqi H, Fangrui Y, Yongyan Y, Yunjian J, Wenhui Z, Kun C, et al. miR-455 functions as a tumor suppressor through targeting GATA6 in colorectal cancer. Oncol Res. 2019;27(3):311\u20136.","journal-title":"Oncol Res"},{"key":"6361_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.csbj.2015.04.003","volume":"13","author":"D Ayers","year":"2015","unstructured":"Ayers D, Mestdagh P, Van Maerken T, Vandesompele J. Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J. 2015;13:307\u201319.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"6361_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.apsb.2016.09.002","volume":"7","author":"X An","year":"2017","unstructured":"An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7(1):38\u201351.","journal-title":"Acta Pharm Sin B"},{"key":"6361_CR39","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.2147\/OTT.S266541","volume":"13","author":"S Li","year":"2020","unstructured":"Li S, Wu Y, Zhang J, Sun H, Wang X. Role of miRNA-424 in cancers. Onco Targets Ther. 2020;13:9611\u201322.","journal-title":"Onco Targets Ther"},{"key":"6361_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.597835","volume":"8","author":"T Shimizu","year":"2020","unstructured":"Shimizu T, Fujii T, Sakai H. The relationship between actin cytoskeleton and membrane transporters in cisplatin resistance of cancer cells. Front Cell Dev Biol. 2020;8: 597835.","journal-title":"Front Cell Dev Biol"},{"key":"6361_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620907","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin L, Yang Y, Zhu W, Xian Y, Han Z, Huang H, et al. Heat shock protein 90 triggers multi-drug resistance of ovarian cancer via AKT\/GSK3beta\/beta-catenin signaling. Front Oncol. 2021;11: 620907.","journal-title":"Front Oncol"},{"issue":"8","key":"6361_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118728","volume":"1867","author":"P Kumar","year":"2020","unstructured":"Kumar P, Devaki B, Jonnala UK, Amere SS. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression. Biochim Biophys Acta Mol Cell Res. 2020;1867(8): 118728.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"8","key":"6361_CR43","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1158\/1535-7163.MCT-08-1186","volume":"8","author":"M Loignon","year":"2009","unstructured":"Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther. 2009;8(8):2432\u201340.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6361_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","volume":"32","author":"M Marchesini","year":"2017","unstructured":"Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D\u2019Anca M, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88\u2013100.","journal-title":"Cancer Cell"},{"issue":"1","key":"6361_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12967-023-04249-6","volume":"21","author":"YJ Shi","year":"2023","unstructured":"Shi YJ, Fang YX, Tian TG, Chen WP, Sun Q, Guo FQ, et al. Discovery of extracellular vesicle-delivered miR-185-5p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer. J Transl Med. 2023;21(1):421.","journal-title":"J Transl Med"},{"key":"6361_CR46","doi-asserted-by":"crossref","unstructured":"Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, et al. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight. 2017;2(13).","DOI":"10.1172\/jci.insight.90036"},{"issue":"7","key":"6361_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3727\/096504020X15965357399750","volume":"28","author":"A Patel","year":"2021","unstructured":"Patel A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, et al. Outcomes of patients with acute myeloid leukemia who relapse after 5 years of complete remission. Oncol Res. 2021;28(7):811\u20134.","journal-title":"Oncol Res"},{"issue":"17","key":"6361_CR48","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res. 2019;25(17):5329\u201341.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6361_CR49","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Epigenetic strategies to boost CAR T cell therapy. Mol Ther. 2021;29(9):2640\u201359.","journal-title":"Mol Ther"},{"issue":"3","key":"6361_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158\u201373.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06361-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T17:04:30Z","timestamp":1744304670000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6361"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06361-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"421"}}